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A B S T R A C T
The pyrazol compounds are known to possess antipyretic, analgesic and anti-inﬂammatory activities. This
study was conducted to investigate the peripheral antinociceptive effect of the pyrazole compound
5-(1-(3-Fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole (LQFM-021) and involvement of opioid receptors
and of the NO/cGMP/KATP pathway. The oral treatments in mice with LQFM-021 (17, 75 or 300 mg/kg)
decreased the number of writhing. In the formalin test, the treatments with LQFM-021 at doses of 15,
30 and 60 mg/kg reduced the licking time at both neurogenic and inﬂammatory phases of this test. The
treatment of the animals with LQFM-021 (30 mg/kg) did not have antinociceptive effects in the tail-ﬂick
and hot plate tests. Furthermore, pre-treatment with naloxone (3mg/kg i.p.), L-name (10mg/kg i.p.), ODQ
(10mg/kg i.p.) or glibenclamide (3mg/kg i.p.) antagonized the antinociceptive effect of LQFM-021 in both
phases of the formalin test. In addition, it was also demonstrated that the treatments of mice with
LQFM-021(15, 30 and 60 mg/kg) did not compromise the motor activity of the animals in the chimney
test. Only the highest dose used in the antinociceptive study promoted changes in the open ﬁeld test
and pentobarbital-induced sleep test, thus ruling out possible false positive effects on nociception tests.
Our data suggest that the peripheral antinociception effects of the LQFM-021 were mediated through
the peripheral opioid receptors with activation of the NO/cGMP/KATP pathway.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Pain is one of the most prevalent facts that limits productivity and
reduce the quality of life. Although there are many effective analge-
sics, there is some concern regarding their safety and side-effects. The
identiﬁcation of compounds that can treat the pain with low induc-
tion of side-effects remains a major challenge in research [1,2].
Nitricoxide (NO) isknownasan important signalingmolecule regu-
latingawiderangeofphysiological,biochemicalandmolecularprocesses
[3].TheNOhasarole insynaptic transmissioninboththecentralnervous
system(CNS) andperipheral. Some studies havebeenassociatednitric
oxide with antinociceptive effect [4,5]. The synthesis of the NO is me-
diated for different isoforms of nitric oxide synthase (NOS), which
enzymatically converts L-arginine to L-citrulineandNO[6].After its for-
mation,NOactivates theguanylatecyclaseenzyme,which is responsible
for the increase in intracellular levels of cGMP resulting in peripheral
antinociceptive effect [4,7].
Works have been showed that opioid receptor agonist induces pe-
ripheral antinociception, which was associated with activation of the
NO/cGMPpathway[4,8].Theperipheralantinociceptiveeffectsofvarious
drugshavebeenimplicatedintheactivationof theNO/cGMP/KATPchannel
pathway, such as morphine [4,9], dipyrone [10], diclofenac [11] and
xylazine [12].
The agents that promote the release of nitric oxide, in the pe-
riphery, antagonize the hyperalgesia induced by inﬂammatory stimuli
and phosphodiesterase inhibitors, enzymes that inactivate cGMP,
potentiate the analgesic effects of these drugs [13,14].
Pyrazole compounds have been reported that have several biolog-
ical activities such as antimicrobial, antineoplastic, anti-inﬂammatory,
antipyretic and antinociceptive activities [15]. In this context, new
pyrazole derivatives are reported by their antinociceptive, anti-
inﬂammatory and antipyretic effects in different animalmodels [16–21].
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Martins et al. [22] showed that a new synthetic derivative of
pyrazole (LQFM021) is a possible PDE-3 inhibitor and has
vasorelaxant activity and low toxicity. The aim of this work was to
evaluate the antinociceptive effect of a new pyrazole compound,
LQFM-021, and investigate the involvement of the opioid receptor
and NO/cGMP/ATP-sensitive K+ channel pathway in this effect.
2. Materials and methods
2.1. Structure of LQFM021
The compound 5-(1-(3-ﬂuorophenyl)-1H-pyrazol-4-yl)-2H-
tetrazole (LQFM-021) was synthesized in to “Laboratório de Química
Farmacêutica Medicinal” (LQFM), Faculty of Pharmacy, Federal Uni-
versity of Goiás, according to synthetic route described by Martins
et al. [22]. The chemical structure of compound LQFM-021 is shown
in Fig. 1.
2.2. Animals
Experiments were performed using male Swiss albino mice
(25–30 g) from the Central Animal House of the Federal University
of the State of Goiás (UFG). Animals were kept in plastic cages at
22 ± 2 °C with free access to pellet food and water and on a 12 h
light/dark cycle, in compliance with the International Guiding
Principles for Biomedical Research Involving Animals. The animals
were acclimatized for 7 days before the beginning of the
experiments. All experimental protocols were developed according
to the principles of ethics and animal welfare designated by the
Ethics Committee on Animal Experimentation. The experimental
protocols were approved by the Ethic Commission of UFG (number:
17/13).
2.3. Drugs and chemicals
The chemicals used in this study were LQFM-021, synthesized
in to “Laboratório de Química Farmacêutica Medicinal” (LQFM)
(Faculty of Pharmacy, Federal University of Goiás), acetic acid (Merck,
USA), DMSO (Sigma Chemical, USA); formaldehyde (Synth, Brazil),
glibenclamide (Sigma-Aldrich, St. Louis, MO, USA), indomethacin
(Indocid®, Merck Sharp & Dohme Farmac; Goiarmacê), L(+)-
arginine (Acrôs organics, EUA), NG-nitro-L-arginine methyl ester (L-
name) (Cayman Chemical Company, USA), Morphine hydrochloride
(Dimorf®, Cristalia, SP, Brazil), naloxone chloridrate (Narcan®,
Cristalia, SP, Brazil), 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one
(ODQ) (Sigma-Aldrich, St. Louis, MO, USA), pentobarbital (Abbott,
Brazil); LQFM-021was dissolved in 10% DMSO in saline and all other
drugs were dissolved in 0.9% saline.
2.4.Nociceptive tests
2.4.1. Acetic acid-induced abdominal writhing test
The acetic acid-induced nociception was performed as described
previously by Koster et al. [23]. Groups of mice (n = 8) were treated
by gavage (p.o.) with vehicle (10% DMSO 10 mL/kg), LQFM-021 (17,
75 and 300mg/kg) or indomethacin (10 mg/kg, positive control for
antinociceptive activity) 60min before the application of acetic acid
solution (1.2% v/v; 10 mL/kg, i.p.). The number of abdominal
constrictions (writhing) was counted for each animal, over a period
of 30 min after acetic acid injection, and the results are expressed
as the means ± SEM of number of writhing.
2.4.2. Formalin test
The formalin-induced nociception was performed as described
previously byHunskaar et al. [24]. Groups ofmice (n = 8)were treated
by gavage (p.o.) with vehicle (10% DMSO 10 mL/kg), LQFM-021 (7.5,
15, 30 and 60 mg/kg) or indomethacin (10 mg/kg – positive control
for antinociceptive activity in the secondphase) ormorphine (5mg/kg
s.c. –positive control for antinociceptive activity in theﬁrst and second
phase). Following sixty minutes after treatment by gavage (p.o.) or
thirty minutes by (s.c.) was administrated of 20 μL of 3% formalin
(in saline) into the plantar surface of the right hind paw. After phlo-
gistic agent injection, the mice were placed into an acrylic box and
a mirror was placed under the boxes to enable unhindered obser-
vation of the formalin-injected paw for 30 min. Pain reaction time
(licking time) was assessed during two periods, 0–5 min, the ﬁrst
phase (neurogenic pain caused by direct stimulation of the
nociceptors), and from 15 to 30 min, the second phase (inﬂamma-
tory pain causedby release of inﬂammatorymediators). These results
are expressed as the means ± SEM in seconds.
2.4.3. Tail ﬂick test
The tail ﬂick test was performed as described previously by
D’Amour and Smith [25]. The time taken to ﬂick the tail (latency)
when the tail was exposed to a heat source, using the analgesimeter.
The animals were divided into three experimental groups (n = 8)
consisting of animals treated with vehicle (10% DMSO,
10 mL/kg, p.o.), LQFM-021 (30 mg/kg, p.o.) or morphine (5 mg/kg,
s.c. – positive control for antinociceptive activity). The latency to
pain reaction was measured at −30, 0, 30, 60, 90 and 120 min after
treatment. A cut-off of 15 s was set. This test was conducted using
an analgesimeter (Insight). The results are expressed asmeans ± SEM
in seconds at the different times.
2.4.4. Hot plate test
The hot plate test was performed as described previously by
Woolfe andMacDonald [26]. The hot-plate test is a model for study-
ing supraspinally acting analgesic compounds. The latency (in
seconds) to the reaction of the mice to thermal stimuli, as ex-
pressed by licking, shaking or lifting of the hind paws, on a hot-
platemaintained at 55.5 ± 0.5 °C. The animals were divided into three
experimental groups (n = 8) consisting of animals treatedwith vehicle
(10% DMSO, 10 mL/kg, p.o.), LQFM-021 (30 mg/kg, p.o.) or mor-
phine (5 mg/kg, s.c. – positive control for antinociceptive activity).
The latency to pain reaction was measured at −30, 0, 30, 60, 90, 120
and 150min after treatment. A cut-off of 20 s was set. This test was
conducted using a hot plate (Insight). The results are expressed as
means ± SEM in seconds at different times.
2.5. Analysis of the possible mechanism action
2.5.1. Involvement of opioid receptors
To evaluate the involvement of opioid receptors in the
antinociceptive effect of LQFM-021 in the formalin test, the mice
(n = 8) were pre-treated with saline (10 mL/kg i.p.) or (naloxone,
Fig. 1. Chemical structure of compound LQFM-021: 5-(1-(3-ﬂuorophenyl)-
1H-pyrazol-4-yl)-2H-tetrazole.
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3 mg/kg i.p. – non-selective opioid antagonist) 15 min before
of the treatment with vehicle (10% DMSO 10 mL/kg), LQFM-021
(30 mg/kg, p.o.), indomethacin (10 mg/kg p.o.) or morphine
(5 mg/kg s.c.). Following sixty minutes after treatment by
gavage (p.o.) or thirty minutes by subcutaneous administration (s.c.)
the animals received formalin (3% v/v) and the experiment
proceeded as discussed in section 2.4.2. [24,27].
2.5.2. Involvement of the NO pathway
To investigate the role of nitric oxide in the antinociceptive effect
of LQFM-021 in the formalin test, the mice (n = 8) were pre-
treated with L-name (10 mg/ kg, i.p. – NO synthase inhibitor) or
saline (10 mL/kg i.p.) after 15 min, were treated with vehicle
(10 mL/kg p.o.), LQFM-021 (30 mg/kg, p.o.), L-arginine (600 mg/kg,
i.p.) or morphine (5 mg/kg s.c.). Following sixty minutes after treat-
ment by gavage (p.o.) or thirty minutes by (i.p.), the animals received
formalin (3% v/v) and the experiment proceeded as discussed in
section 2.4.2. As described previously with slight modiﬁcations by
Perimal et al. [28] and Mansouria et al. [29].
2.5.3. Involvement of cyclic guanosine monophosphate (cGMP)
pathway
To assess the possible involvement of cGMP in the antinociceptive
effect of LQFM-021 in the formalin test, the mice (n = 8) were pre-
treated with saline (10 mL/kg i.p.) or ODQ (10 mg/kg i.p. – guanylyl
cyclase inhibitor) 15 min before treatment with vehicle
(10mL/kg p.o.) or LQFM-021 (30mg/kg, p.o.). Following sixtyminutes
after treatment by gavage (p.o.) the animals received formalin
(3% v/v) and the experiment proceeded as discussed in section 2.4.2.
As described previously with slight modiﬁcations by Perimal et al.
[28] and Mansouria et al. [29].
2.5.4. Involvement of ATP-sensitive K+ channel
To investigate the role of K+ channel in the antinociceptive effect
of LQFM 021 in the formalin test, the mice (n = 8) were pre-
treated with saline (10 mL/kg i.p.) or glibenclamide (10 mg/kg,
i.p. – speciﬁc K+ ATP blocker channel) 15 min before treatment with
vehicle (10mL/kg p.o.) or LQFM-021 (30mg/kg, p.o.). Following sixty
minutes after treatment by gavage (p.o.) the animals received for-
malin (3% v/v) and the experiment proceeded as discussed in section
2.4.2. As described previously by Perimal et al. [28] and Mansouria
et al. [29], with slight modiﬁcations.
2.6. Evaluation of behavioral alterations
2.6.1. Chimney test
The chimney test permits the detection of muscle relaxing
agents and/or drugs that producemotor incoordination. Brieﬂy, after
60 minutes of treatment with 10 mL/kg vehicle (10% DMSO
10 mL/kg p.o.), LQFM-021 (15, 30 and 60 mg/kg, p.o.) or after 30
minutes of treatment withmorphine (5mg/kg s.c.), the animals were
(n = 8) placed in the tube (25 cm length, 3 cm diameter) with a rough
inner surface. Motor impairments were indicated by the animals’
inability to climb backwards up a tube at time of 30 seconds. The
results are expressed as the means ± SEM, as described by Coleta
et al. [30].
2.6.2. Open ﬁeld test
The open ﬁeld test assessed mice ambulatory behavior and
detects anxiolytic-like or anxiogenic-like agents. The open ﬁeld area
is made of white acrylic (40 cm diameter and 30 cm wall height).
The ﬂoor had eight squares of equal area. After 60 minutes of treat-
ment with 10 mL/kg vehicle (10% DMSO 10 mL/kg p.o.), LQFM-
021 (15, 30 and 60 mg/kg, p.o.) or after 30 minutes of treatment
with morphine (5 mg/kg s.c.), animals (n = 8) were placed individ-
ually at the center of the open ﬁeld and observed for 5 min. The
exploratory activities of animals were registered: square invaded,
square invaded and time spent in the periphery, rearings, groom-
ing, immobility and fecal boluses. The results are expressed as the
means ± SEM as described by Archer [31].
2.6.3. Pentobarbital-induced sleeping test
This sleeping test is used todetect agentswith sedative/depressant
or stimulant effects, stimulant drugs reduce sleeping time and de-
pressant drugs increase this time. After 60minutes of treatmentwith
10 mL/kg vehicle (10% DMSO 10mL/kg p.o.), LQFM-021 (15, 30 and
60 mg/kg, p.o.) or after 30 minutes of treatment with morphine
(5 mg/kg s.c.), all groups of mice (n = 8) were treated with sodium
pentobarbital (40 mg/kg i.p. – hypnosis inducer). The time elapsed
between the loss and subsequent recovery of the righting reﬂexwas
taken as the latency (s) and sleeping duration (min). The results are
expressed as themeans ± SEM of the latency and sleeping duration
as described by Carlini and Burgos [32].
2.7. Statistical analysis
The data were analyzed statistically by One-way ANOVA, fol-
lowed by Tukey’s test as the post hoc test or Two-way ANOVA,
followed by post-hoc Bonferroni Test [33]. All statistical analyses
were carried out using GraphPad InStat® version 5.00. Values of
P ≤ 0.05 are considered signiﬁcant.
3. Results
3.1. Antinociceptive analysis
3.1.1. Writhing test
In the acetic acid-induced writhing test, the treatment with
LQFM-021 at the tested doses of 17, 75 and 300 mg/kg decreased
the number of writhing, when compared to the control group of
61.5 ± 5.3 to 32.3 ± 6.2, 29.7 ± 4.7 22.1 ± 2.3, respectively. The group
treated with indomethacin (10 mg/kg p.o.), positive control, also de-
creased signiﬁcantly the number of writhings 26.1 ± 2.8 (Fig. 2).
3.1.2. Formalin test
In the ﬁrst phase of the formalin test, animals treatedwith vehicle
showed the licking time (s) of 74.00 ± 3.02 and in the second phase
of 177.6 ± 22.9. The treatment with LQFM-021 15, 30 and 60mg/kg
showed signiﬁcant antinociceptive activity when compared to the
control group in both phases of this test (in the ﬁrst phase:
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Fig. 2. Effect of LQFM-021 (17, 75 and 300mg/kg p.o.) on the number of acetic acid-
induced writhing in mice (n = 8). Vehicle (Veh; 10% DMSO 10 mL/kg p.o.).
Indomethacin (Indo, 10 mg/kg p.o.) was used as positive control. Vertical bars rep-
resent mean ± SEM of number of writhings in 30 min for each experimental group.
*** p ≤ 0.001 according to ANOVA followed by post-hoc Tukey’s test.
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49.00 ± 5.8, 47.9 ± 4.4 and 42.7 ± 3.6, respectively, and in the second
phase: 97.3 ± 20.6, 72.4 ± 13.7 and 82.7 ± 11.1, respectively). The group
treated with indomethacin (10mg/kg p.o.), anti-inﬂammatory pos-
itive control, decreased signiﬁcantly the licking time (s) only in the
second phase (74.1 ± 5.5). However, morphine (5 mg/kg s.c.),
antinociceptive positive control, decreased signiﬁcantly in both
phases of this test (ﬁrst phase: 8.87 ± 4.46 and second phase:
11.8 ± 9.5). (Fig. 3).
3.1.3. Tail ﬂick test
In the thermal nociception test, tail-ﬂick, the treatment with
LQFM-021 (30mg/kg, p.o.) manifested no signiﬁcant antinociceptive
activity when compared to the control group (vehicle), the mor-
phine (5 mg/kg, s.c. – opioid agonist) demonstrated signiﬁcant
antinociception at the time of 30, 60, 90, 120 and 150min after treat-
ment (Fig. 4).
3.1.4. Hot plate test
In the thermal nociception test, hot plate, the treatment with
LQFM-021 (30mg/kg, p.o.) manifested no signiﬁcant antinociceptive
activity when compared to the control group (vehicle), the
morphine (5 mg/kg, s.c. – opioid agonist) demonstrated signiﬁcant
antinociception at the time of 30, 60, 90 and 120min after treatment
(Fig. 5).
3.2. Analysis of the possible mechanism of LQFM 021 action
3.2.1. Involvement of opioid receptors
The administration of the non-selective opioid receptor antag-
onist naloxone (3 mg/kg, i.p.), given 15 min prior to test, affected
the antinociceptive activity produced by LQFM-021 30mg/kg in both
phases of the formalin test. The administration of naloxone alone,
in the dose tested, did not affect formalin-induced nociception
(Fig. 6).
3.2.2. Involvement of NO pathway
The involvement of the NO pathway was analyzed with the pre-
treatment of the mice with L-name, NO synthase (NOS) inhibitor
(10 mg/kg, given 15 min prior to test). When L-name was admin-
istered per se, in the dose tested, it was not notably different from
the control group. This dose was able to signiﬁcantly reverse the
antinociceptive activity exhibited by LQFM-021 (30 mg/kg p.o.) in
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Fig. 3. Effect of LQFM-021 (7.5, 15, 30 and 60 mg/kg p.o.) on the formalin test in mice (n = 8). Indomethacin (10 mg/kg p.o.) and morphine (5 mg/kg s.c.) on the licking
time (s) were used as positive control of test, during the ﬁrst (0–5 min) and second phase (15–30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds.
**p ≤ 0.01 and *** p ≤ 0.001(compared with control group) and # p ≤ 0.05, # # p ≤ 0.01 e # # # p ≤ 0.001 (compared with second phase control group) according to ANOVA
followed by post-hoc Tukey’s test.
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Fig. 4. Effect of LQFM-021 (30 mg/kg p.o.), and morphine (5 mg/kg s.c. – positive
control) on the tail-ﬂick test, in mice (n = 8). The values are expressed as mean ± SEM
of the latency for the nociceptive behavior, in seconds. *p ≤ 0.05 and *** p ≤ 0.001
(compared with control group) according to two-way ANOVA followed by post-
hoc Bonferroni test.
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Fig. 5. Effect of LQFM-021 (30 mg/kg p.o.), and morphine (5 mg/kg s.c. – positive
control) on the hot plate test, in mice (n = 8). The values are expressed as mean ± SEM
of the latency for the nociceptive behavior, in seconds. *** p ≤ 0.001 (compared with
control group) according to two-way ANOVA followed by post-hoc Bonferroni Test.
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both phases. The L-name in the dose did not reverse the
antinociceptive effect of the morphine (5mg/kg s.c.) in both phases,
but reverse the effect of the L-arginine (600 mg/kg i.p.), nitric oxide
precursor, in the second phase (Fig. 7).
3.2.3. Involvement of cyclic guanosine monophosphate (cGMP)
pathway
The intraperitoneal administrations of ODQ (1 mg/kg i.p.) given
15 min prior to the test, signiﬁcantly reversed the antinociceptive
effect induced by LQFM-021 in both phases of the formalin test. The
administration of ODQ per se, in the dose tested, did not affect
formalin-induced nociception (Fig. 8).
3.2.4. Involvement of ATP-sensitive K+ channel pathway
The intraperitoneal administrations of glibenclamide (3 mg/kg,
i.p.) given 15 min prior to the test, signiﬁcantly reversed the
antinociceptive effect induced by LQFM-021 in both phases of the
formalin test. The administration of glibenclamide per se, in the dose
tested, did not affect formalin-induced nociception (Fig. 9).
3.3. Behavioral alterations
3.3.1. Chimney test
The treatment with LQFM-021 (15, 30 and 60 mg/kg) did not
induce impairment of motor coordination in the chimney test; while
with morphine (5mg/kg) an impairment of motor coordination was
observed (Table 1).
3.3.2. Open ﬁeld test
LQFM-021, at the doses used in the nociception tests (15 and
30mg/kg), did not alter signiﬁcantly the parameters observed in the
open ﬁeld test. Only the dose of 60 mg/kg increased the total lo-
comotion, peripheral locomotion (squares crossed and time in the
periphery). On the other hand, morphine increased the animals’ ex-
ploratory activity and altered other parameters of the open ﬁeld
(Table 2).
3.3.3. Pentobarbital-induced sleep test
Treatment with LQFM-021 (30 and 60 mg/kg) signiﬁcantly de-
creased sleep latency (s) from 157.4 ± 4.7 to 137.9 ± 5.5 and
121.9 ± 3.8, respectively; only the dose of 60 mg/kg increased sig-
niﬁcantly the sleeping time (min) to 96.6 ± 6.5 when compared to
the control group of 55.8 ± 5.15, while morphine did not alter latency
time but increased sleeping duration to 85.4 ± 6.7 min (Table 1).
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Fig. 6. Effect of pre-treatment with saline (10mL/kg i.p.) or the non-selective opioid
receptor antagonist naloxone (3 mg/kg i.p.) on the LQFM-021 (30 mg/kg p.o.)
antinociceptive effect in the ﬁrst phase (A) and second phase (B) of the formalin test,
in mice (n = 8). Vertical bars represent mean ± SEM of pain reaction time, in seconds.
* p ≤ 0.05, **p ≤ 0.01 and *** p ≤ 0.001 (compared with control group) and # # p ≤ 0.01
and # # # p ≤ 0.001 (compared with respectively treated group) according to ANOVA
followed by post-hoc Tukey’s test. Abbreviations: Indo: indomethacin; Nal: nalox-
one; Sal: saline.
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Fig. 7. Effect of pre-treatment with saline (10 mL/kg i.p.) or L-Name (10 mg/kg i.p.)
given 15 min prior to test, on the LQFM-021 (30 mg/kg p.o.), L-arginine (600 mg/kg,
i.p.) andmorphine (5mg/kg s.c.) antinociceptive effect in the ﬁrst phase (A) and second
phase (B) of the formalin test, in mice (n = 8). Vertical bars represent mean ± SEM
of pain reaction time, in seconds. Vertical bars represent mean ± SEM of pain reac-
tion time, in seconds. **p ≤ 0.01 and *** p ≤ 0.001 (compared control group) and #
# p ≤ 0.01 e # # # p ≤ 0.001 (compared with respectively treated group) according
to ANOVA followed by post-hoc Tukey’s test. Abbreviations: Sal: saline; Veh: vehicle;
L-Arg: L-arginine; Mor: morphine.
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4. Discussion
Pain is a health problem, and there is a need for new drugs that
provide effective and safe treatment of pain [34]. Since previous
studies have shown that pyrazole derivatives have antinociceptive
activity with limited adverse effects, these compounds are an in-
teresting source for novel analgesic drugs [21,35–37].
The pyrazole derivative LQFM-021 was originally designed
through molecular hybridization frommilrinone and cilostazol. The
authors showed by computational molecular docking analysis which
LQFM-021 is a possible inhibitor of PDE-3. In addition, the authors
also viewed this pyrasole induced the relaxation of isolated arter-
ies to alter the ﬂow of K+ and Ca2+ through the cell membrane. In
addition LQFM 021waswell toleratedwhen administered orally [22].
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Fig. 8. Effect of pre-treatment with saline (10mL/kg i.p.) or soluble cGMP inhibitor ODQ (10mg/kg i.p.) given 15min prior to test, on the LQFM-021 (30mg/kg p.o.), antinociceptive
effect in the ﬁrst phase (A) and second phase (B) of the formalin test, in mice (n = 8). Vertical bars represent mean ± SEM of pain reaction time, in seconds. Vertical bars
represent mean ± SEM of pain reaction time, in seconds. **p ≤ 0.01 (compared control group) and # # p ≤ 0.01 (compared with respectively treated group) according to ANOVA
followed by post-hoc Tukey’s test. Abbreviations: Sal: saline; Veh: vehicle.
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Fig. 9. Effect of pre-treatment with saline (10 mL/kg i.p.) KATP channel blocker glibenclamide (3 mg/kg i.p.) given 15 min prior to test, on the LQFM-021 (30 mg/kg p.o.),
antinociceptive effect in the ﬁrst phase (A) and second phase (B) of the formalin test, in mice (n = 8). Vertical bars represent mean ± SEM of pain reaction time, in seconds. Ver-
tical bars represent mean ± SEM of pain reaction time, in seconds. **p ≤ 0.01 (compared control group) and # # p ≤ 0.01 (compared with respectively treated group) according
to ANOVA followed by post-hoc Tukey’s test. Abbreviations: Sal: saline; Veh: vehicle; Glib: glibenclamide.
Table 1
Effects of LQFM-021 andmorphine on chimney and pentobarbital-induced sleep tests.
Results are expressed as mean ± SEM of groups of mice (n = 8) treated with vehicle
10mL/kg, p.o. (Control), LQFM-021 (15, 30 and 60mg/kg, p.o.) or morphine (5mg/kg
s.c.). * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, comparedwith control group using ANOVA
followed by post-hoc Tukey’s test.
Treatments Chimney Sleeping test
Time (s) Latency (s) Duration (min)
Vehicle 10 mL/kg 4.1 ± 0.41 157.5 ± 4.74 55.8 ± 5.15
LQFM-021 15 mg/kg 5.5 ± 0.53 138.1 ± 6.48 57.2 ± 4.70
LQFM-021 30 mg/kg 5.7 ± 0.65 137.9 ± 5.78* 63.6 ± 5.80
LQFM-021 60 mg/kg 4.6 ± 0.65 121.9 ± 3.83*** 96.6 ± 6.50***
Morphine 5 mg/kg 8.8 ± 1.3 ** 159.8 ± 5.76 85.4 ± 6.70***
Table 2
Effect of LQFM-021 and morphine on the open ﬁeld test. Results are expressed as mean ± SEM of groups of mice (n = 8) treated with vehicle 10 mL/kg, p.o. (Control), LQFM-021
(15, 30 and 60 mg/kg, p.o.) or morphine (5 mg/kg s.c.). * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, compared with control group using ANOVA followed by post-hoc Tukey’s test.
Treatments Total square
crossed
Square crossed
in the periphery
Time spent in the
periphery (s)
Rearing Grooming Immobility (s) Fecal boluses
Vehicle 10 mL/kg 124.5 ± 7.64 61.3 ± 4.69 161.9 ± 7.48 66 ± 4.77 2.11 ± 0.77 9.88 ± 2.16 1.3 ± 0.3
LQFM-021 15 mg/kg 131.8 ± 7.54 63.4 ± 4.08 186.2 ± 954 74.5 ± 3.91 1.63 ± 1.17 6.70 ± 2.02 1.5 ± 0.5
LQFM-021 30 mg/kg 133.5 ± 5.66 71.2 ± 6.06 183.0 ± 10.37 69.4 ± 2.24 2.00 ± 0.91 6.44 ± 1.92 1.5 ± 0.52
LQFM-021 60 mg/kg 158.3 ± 8.80* 89.3 ± 8.12* 213.9 ± 14.65* 78.3 ± 8.95 2.80 ± 1.24 9.74 ± 3.80 1.6 ± 0.45
Morphine 5.0 mg/kg 152 ± 8.91* 90.1 ± 2.34** 194.7 ± 5.74* 47.75 ± 13.06* 0.52 ± 0.30** 8.5 ± 2.46 0.0 ± 0.0***
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Several studies reported evidence that nitric oxide (NO) and cGMP
have an important role in peripheral antinociception induced bymor-
phine [4,9], dipyrone [10], diclofenac [11], xylazine [12], acetylcholine
[38] and rofecoxib [39]. The NO is a controversial neuromediator
in nociception. It is able to produce pro-nociceptive or antinociceptive
effects for central or peripheral pain mechanisms [38]. Duarte et al.
[5] have proposed that the L-arginine/NO/cGMP pathway was in-
volved in peripheral antinociception.
The present study demonstrates that LQFM-021 is able to produce
antinociceptive effects in the acetic acid-induced writhing test and
both phases of the formalin test. The administration of the acetic
acid induced writhing which induced acute peripheral inﬂamma-
tory reaction, this a visceral pain model that is widely used to
evaluate antinociceptive activity [21,40]. The treatment with
LQFM-021 caused a signiﬁcant decrease in the number of acetic acid-
induced abdominal writhing. Based on a similar effect observed with
all doses, we decided to work with lower doses in other tests.
The formalin administration causes a biphasic response. The ﬁrst
phase (neurogenic phase) occurs during the ﬁrst 5 min after for-
malin injection and the second phase (inﬂammatory phase) occurs
during the 15–30 minutes after formalin injection [41,42]. This is
a nociception test well described and the pain can be inhibited by
typical analgesic (both phases) and anti-inﬂammatory drugs (second
phase) [24,41]. In this test the results showed that LQFM-021 at
15 mg/kg caused signiﬁcant antinociception in both phases of neu-
rogenic and inﬂammatory pain. The result found did not discriminate
the anti-inﬂammatory activity of the central or peripheral analge-
sic effect.
We further assessed the effects of LQFM-021 using the tail-
ﬂick and hot-plate tests; both are based on measuring the response
of the animal to thermal stimuli where the tail-ﬂickmonitors a spinal
reﬂex, and the hot plate is used for supraspinal reﬂex [41,43]. The
treatment of the animals with LQFM-021 30 mg/kg (p.o.) did not
increase latency in these tests; it was shown that the antinociceptive
effect found in others tests do not involve central mechanisms. The
reference drug morphine, an opioid receptor agonist, induced a sig-
niﬁcant increase in latency, as expected.
Although centrally mediated antinociceptive effect was ex-
cluded, we decided to investigate the participation of opioid receptor
in the mechanism of LQFM-021’s action. Since which opioid recep-
tors on peripheral terminals of afferent nerves can be the sites of
the intrinsic modulation of nociception and drugs with action on
these receptors may lead to analgesic effects in the absence of the
central adverse effects caused by opioids [44].
The formalin test was used to clarify the possible mechanism
of the antinociceptive effect of the compound. This study showed
that the administration of LQFM-021 (30 mg/kg) produced
antinociceptive effects on both the neurogenic and inﬂammatory
phases of the formalin test, and the pre-treatment with naloxone
(3mg/kg), opioid receptor antagonist, completely reversed the effect
produced by LQFM-021 in the ﬁrst phase and partly in the second
phase. These results indicate that this compound has peripheral
antinociceptive activity that involves activation of the opioid re-
ceptor. A similar result was found in the study of the other pyrasole
by Prokopp et al. [19]. Some studies have demonstrated that pe-
ripheral opioid receptors induce peripheral antinociception activating
the L-arginine/NO/cGMP pathway [4,8,44].
The pre-treatment with the NO synthesis inhibitor, L-NAME, com-
pletely reversed the antinociceptive effects of LQFM-021 in the both
phases of the formalin test. These data support the hypothesis that
LQFM-021 could produce an peripheral antinociceptive effect through
the L-arginine/NO/cGMP signaling pathway similar to other anal-
gesic drugs.
The NO/cGMP pathway depends on the synthesis and release of
NO which then activates the guanylate cyclase enzyme responsi-
ble for an increase in the intracellular level of the cGMP [12]. It has
been reported that cGMP plays an important role in the up or
downregulation of nociceptors and is a key mediator in
antinociception [4,45,46]. The pre-treatment with the speciﬁc
guanylate cyclase inhibitor, ODQ, reversed the antinociceptive effect
of LQFM-021 in both phases of the formalin test, as shown by the
involvement of cGMP in its effect. Our results are agree with several
studies showing that peripheral NO and cGMP are important for the
antinociceptive activity of different analgesic drugs [5,6,14,47,48].
Furthermore, substances that inhibit cGMP hydrolysis could in-
crease the activity of substances that signal cGMP pathway, such
as inhibitor of the phosphodiesterase [49,50].
Therefore, due to the hypothesis that activation of the NO/cGMP
pathway could induce antinociception through the opening of K+
channels [9], we researched on the possible involvement of ATP-
sensitive K+ channels in peripheral antinociception induced by
LQFM-021. The sulfonylurea glibenclamide (speciﬁc K+ ATP blocker)
inhibits the antinociceptive effect induced by a NO donor, sodium
nitroprusside, and an analog of cGMP, dibutyryl-cGMP [51,52]. Our
results demonstrated that the pre-treatment with the glibenclamide
antagonized the antinociceptive effect of LQFM-021 in both phases
of the formalin test. Taken together, these data suggest that
LQFM-021 produces a peripheral antinociceptive effect this
compound involved the participation of opioid receptors and
NO/cGMP/KATP pathway.
In addition, to clarify if the analgesic effect is not a result of motor
deﬁcits or sedation, mice were subjected to chimney, open-ﬁeld and
pentobarbital-induced sleep tests after oral administration of
LQFM-021. Our results showed that the treatment with LQFM-021,
in analgesic doses, did not cause an impairment of locomotor activity
in the chimney test. Only the higher dose used in the study of
antinociceptive activity promoted changes in the open ﬁeld and
pentobarbital-induced sleep tests. This result suggested that the
antinociceptive effect of LQFM-021 was not false positive with
peripheral neuromuscular blockade or sedation.
5. Conclusions
In conclusion, this study showed that new pyrazole compound
LQFM-021 produced antinociceptive effects in the acetic acid-
induced writhing and formalin tests. However results of tests of
thermal pain indicate that its action is only peripheral. In addi-
tion, this study suggests that themechanism of antinociceptive action
involved interaction with peripheral opioid receptors and activa-
tion of the NO/cGMP/K(ATP) pathway.
Acknowledgments
The authors are grateful to Dr. Ekaterina A. F. B. Rivera and Lucas
B. do Nascimento for ethical and technical assistance, as well as the
CNPq and CAPES for ﬁnancial support.
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.niox.2015.02.146.
References
[1] J. Jage, Opioid tolerance and dependence. Do they matter?, Eur. J. Pain 9 (2005)
157–162.
[2] J. Milano, S.M. Oliveira, M.F. Rossato, P.D. Sauzem, P. Machado, P. Beck, et al.,
Antinociceptive effect of novel trihalomethyl-substituted pyrazoline methyl
esters in formalin and hot-plate tests in mice, Eur. J. Pharm. Biopharm. 581
(2008) 86–96.
[3] D. Wendehenne, A. Pugin, D. Klessig, J. Durner, Nitric oxide: comparative
synthesis and signaling in animal and plant cells, Trends Plant Sci. 6 (2001)
177–183.
23I.F. Florentino et al./Nitric Oxide 47 (2015) 17–24
[4] S.H. Ferreira, I.D.G. Duarte, B.B. Lorenzetti, The molecular mechanism of action
of peripheral morphine analgesia: stimulation of the cGMP system via nitric
oxide release, Eur. J. Pharmacol. 201 (1991) 121–122.
[5] I.D.G. Duarte, I.R. Dos Santos, B.B. Lorenzetti, S.H. Ferreira, Analgesia by direct
antagonism of nociceptor sensitization involves the L-arginine-nitric oxide cGMP
pathway, Eur. J. Pharmacol. 217 (1992) 225–227.
[6] G.L. Monica, C. Maximino, K.R.M. Oliveira, A. Brasil, M.E. Crespo-Lopez, E.J.O.
Batista, et al., Nitric oxide as a regulatorymolecule in the processing of the visual
stimulus, Nitric Oxide 36 (2014) 44–50.
[7] I.D.G. Duarte, B.B. Lorenzetti, S.H. Ferreira, Peripheral analgesia and activation
of the nitric oxide cyclic GMP pathway, Eur. J. Pharmacol. 186 (1990) 289–293.
[8] D.F. Pacheco, G.M.L. Reis, J.N. Francischi, M.S. Castro, A.C. Perez, I.D.G. Duarte,
Delta-opioid receptor agonist SNC-80 induces peripheral antinociception via
delta 1 and delta 2 receptors and activation of the L-arginine/NO/cGMP pathway,
Life Sci. 78 (2005) 54–60.
[9] A.R.A. Rodrigues, I.D.G. Duarte, The peripheral antinociceptive effect induced
by morphine is associated with ATP-sensitive K+ channels, Br. J. Pharmacol. 129
(2000) 110–114.
[10] D.P. Alves, I.D.G. Duarte, Involvement of ATP-sensitive K+ channels in the
peripheral antinociceptive effect induced by dipyrone, Eur. J. Pharmacol. 444
(2002) 47–52.
[11] D.P. Alves, M.A.F. Tatsuo, R. Leite, I.D.G. Duarte, Diclofenac-induced peripheral
antinociception is associated with ATP-sensitive K+ channels activation, Life Sci.
74 (2004) 2577–2591.
[12] T.R.L. Romero, I.D.G. Duarte, α2-Adrenoceptor agonist xylazine induces
peripheral antinociceptive effect by activation of the L-arginine/nitric oxide/
cyclic GMP pathway in rat, Eur. J. Pharmacol. 613 (2009) 64–67.
[13] A. Vakili, M. Shirvanian, H. Safakhah, A. Rashidy-Pour, Pentoxifylline decreases
allodynia and hyperalgesia in a rat model of neuropathic pain, Daru 19 (2011)
306–311.
[14] W.A. Carvalho, L. Lemônica, Molecular and cellular mechanisms of inﬂammatory
pain. Peripheral modulation and therapeutic advances, Rev. Bras. Anestesiol.
48 (1998) 137–158.
[15] A. Rahman, A.A. Siddiqui, Pyrazoline derivatives: a worthy insight into the recent
advances and potential pharmacological activities, Int. J. Pharm. Sci. Drug Res.
2 (2010) 165–175.
[16] A. Gursoy, S. Demirayak, Synthesis and Preliminary evaluation of new
5-pyrazolinone derivatives as analgesics agents, Eur. J. Med. Chem. 35 (2000)
359–364.
[17] F.R. De Souza, M.R. Figuera, T.T.F. Lima, J. Bastiani, I.B. Barcellos, C.E. Almeida,
et al., 3-Methyl 5-hydroxy-5-trichloromethyl-1H-1-pyrazolcarboxyamide
(MPCA) induces antinociception, Pharmacol. Biochem. Behav. 68 (2001)
525–530.
[18] M.C.M. Godoy, M.R. Figuera, A.E. Flores, M.A. Rubin, M.R. Oliveira, N. Zanatta,
α2-Adrenoceptors and 5-HT receptors mediate the antinociceptive effect of
new pyrazoles, but not of dipyrone, Eur. J. Pharm. Biopharm. 496 (2004)
93–97.
[19] C.R. Prokopp, M.A. Rubin, P.D. Sauzem, A.H. De Souza, D.B. Berlese, R.V. Lourega,
et al., A pyrazolyl-thiazole derivative causes antinociception in mice, Braz. J.
Med. Biol. Res. 39 (2006) 795–799.
[20] P.D. Sauzem, G.S. Sant’Anna, P. Machado, M.M. Duarte, J. Ferreira, C.F. Mello,
et al., Effect of 5-triﬂuoromethyl-4,5-dihydro-1H-pyrazoles on chronic
inﬂammatory pain model in rats, Eur. J. Pharmacol. 616 (2009) 91–100.
[21] D.C. Malvar, R.T. Ferreira, R.A. de Castro, L.L. de Castro, A.C. Freitas, E.A. Costa,
et al., Antinociceptive, anti-inﬂammatory and antipyretic effects of 1.5-diphenyl-
1H-pyrazole-3-carbohydrazide, a new heterocyclic pyrazole derivative, Life Sci.
95 (2014) 81–88.
[22] D.R. Martins, F. Pazini, V.M. Alves, S.S. Moura, L.M. Lião, M.T.Q. Magalhães, et al.,
Synthesis, docking studies, pharmacological activity and toxicity of a novel
pyrazole derivative (LQFM 021) – possible effects on phosphodiesterase, Chem.
Pharm. Bull. 61 (2013) 524–531.
[23] R. Koster, M. Andersons, E.J. Debber, Acetic acid analgesic screening, Fed. Proc.
89 (1959) 418–420.
[24] S. Hunskaar, O.B. Fasmer, K. Hole, Formalin test in mice, useful technique for
evaluation mild analgesia, J. Neurosci. Methods 14 (1985) 69–76.
[25] F.E. D’Amour, F.L. Smith, A method for determining loss of pain sensation, J.
Pharmacol. Exp. Ther. 72 (1941) 74–79.
[26] G. Woolfe, A. MacDonald, The evaluation of the analgesic action of pethidine
hydrochloride, J. Pharmacol. Exp. Ther. 80 (1944) 300–307.
[27] E.A. Costa, R.C. Lino, M.N. Gomes, M.V.M. Nascimento, I.F. Florentino, P.M.
Galdino, et al., Anti-inﬂammatory and antinociceptive activities of LQFM002-A
4-nerolidylcatechol derivative, Life Sci. 92 (2013) 237–244.
[28] E.K. Perimal, M.S. Akhtar, A.S. Mohamad, M.H. Khalid, O.H. Ming, S. Khalid, et al.,
Zerumbone-induced antinociception: involvement of the L-arginine nitric
oxide–cGMP–PKC-K+–ATP channel pathways, Basic Clin. Pharmacol. Toxicol. 108
(2011) 155–162.
[29] M.T. Mansouria, B. Naghizadehc, B. Ghorbanzadehd, Y. Farbood, Central and
peripheral antinociceptive effects of ellagic acid in different animal models of
pain, Eur. J. Pharmacol. 707 (2013) 46–53.
[30] M. Coleta, M.T. Batista, M.G. Campos, R. Carvalho, M.D. Cotrim, T.C.M. De Lima,
Neuropharmacological evaluation of the putative anxiolytic effects of Passiﬂora
edulis Sims, its sub-fractions and ﬂavonoid constituents, Phytother. Res. 20 (2006)
1067–1073.
[31] J. Archer, Tests for emotionality in rats and mice: a review, Anim. Behav. 21
(1973) 205–235.
[32] E.A. Carlini, V. Burgos, Screening farmacológico de ansiolíticos: metodologia
laboratorial e comparação entre diazepam e clorobenzepam, Rev. Assoc. Bras.
Psiquiatr. 1 (1979) 25–31.
[33] R.R. Sokal, F.J. Rohlf, Biometry: the Principles and Practice of Statistics in
Biological Research, second ed., WH Freeman & Co, New York, 1981. 859.
[34] A. Bassols, F. Bosch, J.E. Banos, How does the general population treat their pain?
A survey in Catalonia, Spain, J. Pain SymptomManage. 23 (2002) 318–328.
[35] T. Ochi, T. Fujii, Y. Motoyama, T. Goto, Antinociceptive properties of FR140423
mediated through spinal delta-, but not mu- and kappa-, opioid receptors, Eur.
J. Pharmacol. 380 (1999) 73–79.
[36] T. Ochi, K. Jobo-Magari, A. Yonezawa, K. Matsumori, T. Fujii, Anti-inﬂammatory
and analgesic effects of a novel pyrazole derivative, FR140423, Eur. J. Pharmacol.
365 (1999) 259–266.
[37] P.D. Sauzem, P. Machado, M.A. Rubin, G. da S Sant’anna, H.B. Faber, A.H. de Souza,
et al., Design and microwave-assisted synthesis of 5-triﬂuoromethyl-4,5-
dihydro-1H-pyrazoles: novel agents with analgesic and anti-inﬂammatory
properties, Eur. J. Med. Chem. 43 (2008) 1237–1247.
[38] I.D.G. Duarte, B.B. Lorenzetti, S.H. Ferreira, Acetylcholine induces peripheral
analgesia by the release of nitric oxide, Eur. J. Pharmacol. 186 (1990) 289–293.
[39] M. Déciga-Campos, F.J. López-Muñoz, Participation of the L-arginine–nitric
oxide–cyclic GMP–ATP-sensitive K+ channel cascade in the antinociceptive effect
of rofecoxib, Eur. J. Pharmacol. 484 (2004) 193–199.
[40] Z.A. Zakaria, Z.D. Abdul Ghani, R.N. Raden Mohd Nor, H.K. Gopalan, M.R.
Sulaiman, F.C. Abdullah, Antinociceptive and anti-inﬂammatory activities of
Dicranopteris linearis leaves chloroform extract in experimental animals,
Yakugaku Zasshi 126 (2006) 1197–1203.
[41] D. Le Bars, M. Gozariu, S.W. Cadden, Animal models of nociception, Pharmacol.
Rev. 53 (2001) 597–652.
[42] A. Tjølsen, O.G. Berge, S. Hunskaar, J.H. Rosland, K. Hole, The formalin test: an
evaluation of the method, Pain 51 (1992) 5–17.
[43] R. Arslan, N. Bektas, Antinociceptive effect of methanol extract of Capparis ovata
in mice, Pharm. Biol. 48 (2010) 1185–1190.
[44] N. Vadivelu, S. Mitra, R.L. Hines, Peripheral opioid receptor agonists for analgesia:
a comprehensive review, J. Opioid Manag. 7 (2011) 556–558.
[45] A.S. Mohamad, M.N. Akhtar, S.I. Khalivulla, E.K. Perimal, M.H. Khalid, H.M. Ong,
et al., Possible participation of nitric oxide/cyclic guanosine monophosphate/
protein kinase C/ATP-sensitive K(+) channels pathway in the systemic
antinociception of ﬂavokawin B, Basic Clin. Pharmacol. Toxicol. 108 (2011)
400–405.
[46] S. Moncada, Nitric oxide in the vasculature: physiology and pathophysiology,
Ann. N.Y. Acad. Sci. 811 (1997) 60–69.
[47] L.H. Amarante, I.D.G. Duarte, The kappa-opioid (+/−)-bremazocine elicits
peripheral antinociception by activation of the L-arginine/nitric oxide/cyclicGMP
pathway, Eur. J. Pharmacol. 454 (2002) 19–23.
[48] D. Sachs, F.Q. Cunha, S.H. Ferreira, Peripheral analgesic blockade of
hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-
sensitive K+ channel pathway, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3680–3685.
[49] M.L. Vale, D.E. Rolim, I.F. Cavalcante, R.A. Ribeiro, M.H.L.P. Souza, Role of
NO/cGMP/KATP pathway in antinociceptive effect of sildenaﬁl in zymosan
writhing response in mice, Inﬂamm. Res. 56 (2007) 83–88.
[50] I.D.G. Duarte, S.H. Ferreira, The molecular mechanism of central analgesia
induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP
pathway, Eur. J. Pharmacol. 321 (1992) 171–174.
[51] A.C. Soares, R. Leite, M.A. Tatsuo, I.D. Duarte, Activation of ATP-sensitive K(+)
channels: mechanism of peripheral antinociceptive action of the nitric oxide
donor, sodium nitroprusside, Eur. J. Pharmacol. 400 (2000) 67–71.
[52] A.C. Soares, I.D.G. Duarte, Dibutyryl-cyclic GMP induces peripheral
antinociception via activation of ATP-sensitive K+ channels in the rat PGE2-
induced hyperalgesic paw, Br. J. Pharmacol. 134 (2001) 127–131.
24 I.F. Florentino et al./Nitric Oxide 47 (2015) 17–24
